p53 Gain-of-Function Mutation Induces Metastasis via BRD4-Dependent CSF-1 Expression
Authors:
- Gizem EfeGEGizem Efe
- Karen J. DunbarKDKaren J. Dunbar
- Kensuke SugiuraKSKensuke Sugiura
- Katherine CunninghamKCKatherine Cunningham
- Saul CarcamoSCSaul Carcamo
- Spyros KaraiskosSKSpyros Karaiskos
- Qiaosi TangQTQiaosi Tang
- Ricardo Cruz-AcuñaRCRicardo Cruz-Acuña
- Lois Resnick-SilvermanLRLois Resnick-Silverman
- Jessica PeuraJPJessica Peura
- Chao LuCLChao Lu
- Dan HassonDHDan Hasson
- 7 September 2023
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 13 (12) , 2632-2651
Abstract
TP53 mutations are frequent in esophageal squamous cell carcinoma (ESCC) and other SCCs and are associated with a proclivity for metastasis. Here, we report that colony-stimulating factor-1 (CSF-1) expression is upregulated significantly in a p53-R172H–dependent manner in metastatic lung lesions of ESCC. The p53-R172H–dependent CSF-1 signaling, through its cognate receptor CSF-1R, increases tumor cell invasion and lung metastasis, which in turn is mediated in part through Stat3 phosphorylation and epithelial-to-mesenchymal transition (EMT). In Trp53R172H tumor cells, p53 occupies the Csf-1 promoter. The Csf-1 locus is enriched with histone 3 lysine 27 acetylation (H3K27ac), which is likely permissive for fostering an interaction between bromodomain-containing domain 4 (BRD4) and p53-R172H to regulate Csf-1 transcription. Inhibition of BRD4 not only reduces tumor invasion and lung metastasis but also reduces circulating CSF-1 levels. Overall, our results establish a novel p53-R172H–dependent BRD4–CSF-1 axis that promotes ESCC lung metastasis and suggest avenues for therapeutic strategies for this difficult-to-treat disease. Significance: The invasion–metastasis cascade is a recalcitrant barrier to effective cancer therapy. We establish that the p53-R172H–dependent BRD4-CSF-1 axis is a mediator of prometastatic properties, correlates with patient survival and tumor stages, and its inhibition significantly reduces tumor cell invasion and lung metastasis. This axis can be exploited for therapeutic advantage. This article is featured in Selected Articles from This Issue, p. 2489Keywords
All Related Versions
Funding Information
- National Cancer Institute (P01-CA098101)
- National Cancer Institute (P30CA013696)
- American Cancer Society (American Cancer Society Research Professorship)
- National Cancer Institute (R01CA272903-01)
- National Cancer Institute (F31CA275369-02)
- National Cancer Institute (R35CA220526)
- National Institutes of Health (S10OD026880)
- National Cancer Institute (P30CA196521)
- National Center for Advancing Translational Sciences (Clinical and Translational Science Awards (CTSA) grant UL1TR004419)
This publication has 67 references indexed in Scilit:
- Autocrine CSF-1R signaling drives mesothelioma chemoresistance via AKT activationCell Death & Disease, 2014
- Mutant p53 in Cancer: New Functions and Therapeutic OpportunitiesCancer Cell, 2014
- Mutant p53: one name, many proteinsGenes & Development, 2012
- Autocrine CSF-1 and CSF-1 Receptor Coexpression Promotes Renal Cell Carcinoma GrowthCancer Research, 2012
- Alterations of theTP53Gene in Gastric and Esophageal CarcinogenesisJournal of Biomedicine and Biotechnology, 2012
- Mutant p53 drives multinucleation and invasion through a process that is suppressed by ANKRD11Oncogene, 2011
- Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of TumorigenesisGenes & Cancer, 2011
- ChIP-seq: Using high-throughput sequencing to discover protein–DNA interactionsMethods, 2009
- Crystal Structure of the Human BRD2 BromodomainJournal of Biological Chemistry, 2007
- Oral Cavity and Esophageal Carcinogenesis Modeled in Carcinogen-Treated MiceClinical Cancer Research, 2004